Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Summary

See updated study design under NCT04882735. Phase 3 efficacy and safety of AG10 compared with placebo in subjects with symptomatic Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Timeline

Start

2020-10-21

Primary completion

2024-03-31

Completion

2024-04-30

Outcome

Outcome not reported

Stopped: “After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.”

Drugs

Indications